CADILA HEALTHCARE LTD. - 532321 - Shareholding for the Period Ended December 31, 2018
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2018. For more details, kindly Click here14-01-2019
14-01-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approvals from the USFDA for Betamethasone Dipropionate Cream and Amlodipine & Atorvastatin Tablets12-01-2019
Cadila Pharma inks pact with Norwegian start-up to develop new treatment for heart patients
Cadila Pharmaceuticals Ltd has announced an agreement with Norway-based Inven2's start-up, Serca Pharmaceuticals, to develop a new treatments for hear10-01-2019
Zydus Cadila gets USFDA nod for antipsychotic drug
Zydus Cadila said on Tuesday that it has received final approval from the US health regulator to market antipsychotic drug Aripiprazole tablets. Zydu08-01-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Aripiprazole Tablets08-01-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentation
Revised Investor Presentation07-01-2019
Zydus Cadila gets USFDA nod to market acne drug
Drug firm Zydus Cadila on Saturday said it has received final nod from the US health regulator to market Clindamycin Phosphate and Benzoyl Peroxide29-12-2018
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
We enclose herewith a copy of press release dated December 29, 2018 titled 'Zydus receives final approval from the USFDA for Clindamycin Phosphate and Benzoyl Peroxide Gel'. The contents of the press release give full details. Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.29-12-2018
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives approvals from the USFDA for Doxycycline Hyclate Delayed-Release Tablets and Febuxostat Tablets24-12-2018
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed a copy of press release dated December 15, 2018 titled 'Zydus receives approvals from the USFDA for Albendazole Tablets and Pregabalin Capsules'.15-12-2018